A Phase II Study of Pembrolizumab in Combination With Ibrutinib in the Treatment of Unresectable or Metastatic Melanoma
Phase of Trial: Phase II
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Ibrutinib (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 13 Jun 2017 Status changed from recruiting to suspended.
- 31 Jan 2017 Planned primary completion date changed from 1 Feb 2020 to 1 Feb 2021.
- 31 Jan 2017 Status changed from not yet recruiting to recruiting.